Novavax Inc.’s shares plunged nearly 20 percent in premarket trading on May 10 due to uncertainty over global demand for the company’s COVID-19 vaccine following a slow start to deliveries.

Novavax Inc. filed for emergency use authorization of the company’s COVID-19 vaccine for U.S. adults, a long-awaited step following months of struggles with development and manufacturing problems.

Novavax Inc. said on Oct. 27 the company had completed the real-time submission of an application for the authorization of the Covid-19 vaccine candidate NVX-CoV2373 in the United Kingdom.

The life sciences industry was well-represented on Forbes’ 35th annual list of billionaires, with a handful of names featured in the top 100.

Bharat Biotech’s a two-dose, injectable Covid-19 vaccine Covaxin is authorized in India for ages 12 and up. The company is moving forward with a second vaccine against the novel coronavirus with a different mode of administration. 

India’s export ban on Covid-19 shots risks dragging the battle against the pandemic “back to square one” unless wealthy nations step in to plug a gaping hole in the COVAX global vaccine-sharing scheme, health specialists said on May 20.

The same group at the University of Oxford and the Jenner Institute that developed the AstraZeneca-Oxford Covid-19 vaccine reported that their investigational malaria vaccine, R21/Matrix-M, demonstrated 77 percent efficacy in children over 12 months of follow-up.

COVAX

COVAX will deliver 237 million doses of AstraZeneca’s Covid-19 shot to 142 countries by the end of May as the World Health Organization-backed program steps up the global roll-out of its vaccine supplies.

Many health experts believe that the Covid-19 vaccine candidate NVX-CoV237 from Novavax offers potential advantages over competitors including Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca-Oxford.

Drug developer Novavax Inc. completed enrolling 30,000 volunteers in a late-stage study of the company’s Covid-19 vaccine in the United States and Mexico.